Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD 12.3 billion during Q4 2024, excluding foreign exchange impact. For the full year, revenues rose 7% YOY to USD 48.3 billion, according to the company’s financial report released this week. The US market expanded 9% YOY to USD 8.6 billion in Q4 and 9% to USD 34.1 billion for the full year, while the rest of the world grew 5% to USD 3.7 billion in Q4 and 3% to USD 14.2 billion for the full year.
Growth Portfolio Performance
BMS’ recently launched Growth Portfolio generated USD 6.4 billion in sales during Q4 (+21%) and USD 22.6 billion during the full year (+17%). Within this portfolio, the PD-1 inhibitor Opdivo (nivolumab) achieved USD 9.3 billion in sales for the year, up 3% YOY (excluding sales from Ono Pharmaceutical in Asia). Other key performers included red blood cell maturation agent Reblozyl (luspatercept) with USD 1.77 billion (+76%), CD19-targeted CAR-T therapy Breyanzi (lisocabtagene maraleucel) with USD 747 million (+105%), and cardiac myosin inhibitor Camzyos (mavacamten) with USD 602 million (+161%).
Challenges and Regulatory Milestones
Despite robust growth in its new products, BMS faced challenges with declining sales of cancer therapies Sprycel (dasatinib), Revlimid (lenalidomide), Abraxane (paclitaxel, albumin), and Pomalyst (pomalidomide) due to generic erosion, which partly offset the company’s overall growth. However, BMS achieved multiple clinical and regulatory milestones during Q4, including earning FDA approval for Opdivo Qvantig and the US launch of schizophrenia drug Cobenfy.
2025 Outlook
BMS now expects to achieve up to USD 45.5 billion in revenues in 2025. This outlook reflects the company’s ongoing efforts to drive growth through its innovative product portfolio and strategic initiatives.-Fineline Info & Tech
